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Abstract 
An unusual presentation of Devic’s neuromyelitis optica (NMO) disease associated with 
bilateral internuclear ophthalmoplegia (INO) is described. A 32-year-old pregnant patient 
was diagnosed with NMO. First symptoms were headache and sudden visual loss in her 
right eye (RE). Eighteen months ago, she reported other neurologic symptoms such as 
paresthesia. Based on her visual field, fundoscopy and Ishihara test, she was diagnosed 
with retrobulbar neuritis of the RE. After delivery, new neurologic symptoms resembling 
transverse myelitis appeared. She was treated with methylprednisolone and 
plasmapheresis, which improved her visual acuity; however, a sudden bilateral INO 
appeared, with adduction defect and nystagmus with abduction in both eyes. No 
improvement was obtained after treatment with azathioprine and rituximab. Paresis of 
the legs and the right arm persisted, but double vision and OIN gradually disappeared. At 
the end, the patient had a residual exophoria in the RE and nystagmus with abduction in 
the left eye. Prevalence of NMO is lower than one case per one million inhabitants, and it 
is not likely to affect the encephalic trunk; furthermore, bilateral INO in NMO is rare. Two 
major criteria and at least two of the three minor ones are required to confirm a NMO 
diagnosis, and our patient fulfilled these diagnosis criteria. 
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Introduction 
Devic’s disease, also known as neuromyelitis optica (NMO), is an autoimmune and 
inflammatory disorder that combines optic neuropathy and acute or subacute
 transverse 
myelitis which may occur simultaneously or after some time [1]. 
The main symptoms of Devic’s disease are visual loss and spinal cord dysfunction. The 
typical presentation of optic neuritis is visual impairment with acute decrease of visual 
acuity. Brainstem affection can lead to a sensitivity reduction, muscle weakness and loss 
of bladder and bowel control [2], although unusual conditions as hiccups [3] or 
narcolepsia [4] have also been reported. The most common neurological symptoms are 
legs or limbs weakness (paraparesis or tetraparesis) with sensorial signs.  
The origin of NMO, since Devic defined it in 1870, was unknown and some authors 
thought that it was a variant of multiple sclerosis (MS). In the last years, NMO-IgG 
antibodies have been described as the physiopathological cause of Devic’s disease [5]. The 
antibodies’ target is aquaporin 4, a protein which acts as a water transport channel across 
the astrocyte cell membrane [6]. The function of aquaporin 4 is important for the 
maintenance of the blood-brain barrier [7]. 
Immunosuppressive treatments for NMO have a low effectiveness and prognosis
 is 
poor with some cases having an acute and devastating evolution [8]. Intravenous 
corticosteroids, as methylprednisolone, are usually used to treat new attacks of optic 
neuritis or myelitis. Some authors have reported little evidence for immunosuppressive 
treatment in NMO, especially using mitoxantrone, azathioprine and mycophenolate 
mofetil [9, 10]. 
Internuclear ophthalmoplegia (INO) is a disorder affecting eye movements caused by 
medial longitudinal fasciculus affection. Patients affected by INO present nystagmus in 
one eye when the other eye is in abduction, and it can also cause diplopia. MS is by far the 
most common cause of INO. Usually, INO is unilateral, but it can also affect both sides 
[11]. 
We present a case of a woman diagnosed with NMO who had acute and bilateral INO 
and tetraparesis without response to immunosuppressive treatments. 
Case Report 
A 32-year-old pregnant woman at 34 weeks’ gestation presented to the emergency department 
complaining of headache and sudden reduction of visual acuity in her RE to counting fingers at one 
meter. Her
 medical history revealed neurologic symptoms as paresthesia of the legs and the right arm 18 
months ago.
  
At the visual field exam, altitudinal and centrocecal defects were observed. The patient was 
diagnosed with retrobulbar neuritis in the RE with an abnormal Ishihara test, a relative afferent 
pupillary defect in the RE and normal fundoscopy. Seven days later, RE visual acuity improved to 5/100, 
pupillary reflexes and Ishihara test were normal and the visual field scotoma decreased. One month 
after the initial episode, eye evaluation was normal and visual acuity in the RE was 7/10. Two days after 
delivery, she experienced paraparesis and L’hermitte’s sign. Repeated blood cultures for common 
pathogens and mycobacteria were negative. Serologic testing
 for human immunodeficiency virus, 
human T-lymphotrophic virus, cytomegalovirus, herpes simplex viruses, poliomyelitis and tetanus 
resulted negative. Antinuclear antibodies and antineutrophil cytoplasmic antibodies were negative, but 
anti-DNA
 antibodies were elevated. Hemogram and biochemistry were normal.  
Case Rep Neurol 2010;2:139–144 
DOI: 10.1159/000322428 
Published online: 
November 12, 2010
© 2010 S. Karger AG, Basel 
ISSN 1662–680X 
www.karger.com/crn 
 
 
141
Brain magnetic resonance
 images (MRI) showed no alterations, but a longitudinal  lesion that 
affected four segments was seen in the cervical spinal cord MRI (fig. 1). 
Empirical therapy with methylprednisolone 1 g/day during 3 days (Solumoderin; Pfizer, Madrid, 
Spain) and azathioprine (Imurel; Glaxo-Welcome, Paris, France) was administered, but the patient’s 
neurologic status remained stable. No abnormalities were
 seen on a second brain MRI. 
Three months later, paraparesis improved, but the patient was admitted to the hospital with 
abdominal pain and fever without response to antibiotic therapy (amoxicillin-clavulanic 875/125 mg). 
Two days after admission, she presented acute tetraplegia with loss of sensibility in the cervical area, 
Babinsky sign and areflexia of both legs and of her right arm. The combined anti-infective and steroid 
therapy was administered with absence of clinical improvement. As the patient did not respond to the 
previous treatments, plasmapheresis for 15 consecutive days was performed without initial efficacy [12]. 
Afterwards, a progressive and slow improvement of neurologic symptoms was observed. 
Two months later, the patient presented an acute limitation in adduction of both eyes and bilateral 
nystagmus in abduction which was diagnosed as bilateral INO (online suppl. video 1, 
www.karger.com/doi/10.1159/000322428) (fig. 2a, b). A new spinal cord MRI showed brainstem 
necrosis that affected the encephalic trunk. Two intravenous injections (1 g) of rituximab (Rituxan; 
Genentech Inc., San Francisco, Calif., USA, 2008), an anti-CD20 monoclonal antibody, separated by 2 
weeks in combination with methotrexate were administered to the patient [13]. Suddenly, her systemic 
state worsened and she presented hallucinations and astonishment, needing intravenous nutrition and 
bladder catheter.  
After six months, the patient was still at the hospital with bilateral paresis of the right arm and leg. 
Double vision and INO disappeared, but residual nystagmus of the RE and limitation in adduction of 
the LE persisted (online suppl. video 2). Visual acuity was 9/10 in both eyes; pupilar reflex, Ishihara test, 
visual field and eye fundus were normal. Optical coherence tomography (Stratus OCT 3000; Carl Zeiss 
Meditec, Dublin, Calif., USA) showed slight reduction of the retinal nerve fiber layer (RNFL) thickness 
in the superior and nasal area of the RE and an increase of the RNFL in the superior quadrant of the LE 
(fig. 3). 
Discussion 
The spinal cord damage in NMO can range from inflammatory demyelination to 
necrotic damage of the white and grey matter [6, 14]. Inflammation may also affect the 
brain and sometimes neurologic symptoms suggest acute disseminated encephalomyelitis 
or MS [15]. 
In 2006, the Mayo Clinic proposed a revised set of criteria for the diagnosis of Devic’s 
disease [16]. Our patient fulfilled the two major criteria and two of the three supportive 
criteria: brain MRI not meeting criteria for MS at disease onset, and spinal cord MRI with 
contiguous T2-weighted signal abnormality extending over three or more vertebral 
segments. She was seronegative for NMO-IgG, but the presence of anti-DNA
 antibodies 
suggests an autoimmune disease such as NMO. Some patients with NMO may be 
negative for NMO-IgG, while some patients with NMO-IgG may not fulfill clinical 
criteria for NMO [2, 17]. 
INO is an unusual presentation in a patient with NMO. Typically, the disease affects 
the brainstem, but not the brain nerves; however, unusual conditions of the brain nerves 
in NMO have been reported [18, 19]. 
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Fig. 1. Cervical spinal MRI showing a longitudinal lesion affecting four segments. 
 
 
 
Fig. 2. a, b Eye movements showing limitation in adduction of both eyes and bilateral nystagmus in 
abduction. The cover/uncover and alternate cover test showed an alternating exotrophia (the outturned 
eye refixates inward when the other is covered). 
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Fig. 3. Optical coherence tomography showing slight reduction of the RNFL thickness in the superior 
and nasal quadrants of the RE and an increase of RNFL in the superior quadrant of the LE. 
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